Review articleAge-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review
Section snippets
Material reviewed
We conducted a global review by searching MEDLINE for articles published through September 2010. To identify published articles on HPV serology, we used the following search terms: human papillomavirus, human, serology, serologic tests, antibodies, and immunology. For articles with HPV DNA and serology within the same population, we used the same search terms plus DNA. References cited in identified articles were also reviewed. Eligible studies were restricted to peer-reviewed articles with
Serology results
Of more than 2,000 identified abstracts, 117 studies were included in this review (Table 1). Most study populations were from Europe (35%), followed by North America (27%), Asia and Australia (19%), Central and South America (8%), and Africa (6%). Study participants' ages ranged from a few hours to >90 years. Serological antibodies were typically detected with enzyme-linked immunosorbent assay (ELISA) (78%), whereas competitive Luminex assay (12%), glutathione S-transferase capture assay (9%),
Discussion
This review of more than 138,000 study participants worldwide found that HPV seroprevalence was variable and depended on many factors, including geographic location, gender, and age. These differences across studies are consistent with broad ranges of HPV-16 and −18 seroprevalence and DNA prevalence previously observed [28], [85], [87], [116]. Both HPV-16 and −18 seroprevalences were generally higher in Africa, Central and South America, and North America; and lower in Europe, Asia, and
Summary and implications
Several important points can be drawn from this global review. Seroprevalence and DNA prevalence of oncogenic HPV types were globally more common in women than in men and had distinguishable age trends but varied by geographic region. Using HPV serology data, a measure of cumulative exposure, along with HPV DNA data, a measure of acute infection, can contribute to estimating HPV virus exposure on a population level, which is important for vaccine program implementation. Within the 9–26-year-old
Acknowledgments
This work was supported in part by the National Institutes of Health, Office of the Director, Fogarty International Center, Office of AIDS Research, National Cancer Centre, National Eye Institute, National Heart, Blood and Lung Institute, National Institute of Dental and Craniofacial Research, National Institute on Drug Abuse, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases Health, and NIH Office of Women's Health and Research through the International
References (129)
- et al.
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial
Lancet
(2004) The serological response to papillomaviruses
Semin Cancer Biol
(1999)- et al.
Evaluating the impact of human papillomavirus vaccines
Vaccine
(2009) - et al.
Serological study in Tunisian cervical cancer patients
Pathol Biol (Paris)
(2009) - et al.
Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: Implication for optimal age of human papillomavirus vaccination
J Clin Virol
(2007) - et al.
Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions
Am J Obstet Gynecol
(2005) - et al.
Seroepidemiology as basis for design of a human papillomavirus vaccination program
Vaccine
(2008) - et al.
Immunogenicity and tolerability of an HPV −16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years
Vaccine
(2009) - et al.
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant
J Adolesc Health
(2007) - et al.
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women
J Adolesc Health
(2010)
Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada
Oral Oncol
Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use
Ann Oncol
IARC Monographs on the Evaluation of Carcinogenic Risks to HumansHuman Papillomaviruses
Estimates of worldwide cancer burden in 2008: GLOBOCAN 2008
Int J Cancer
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
N Engl J Med
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
Br J Cancer
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial
JAMA
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study
Am J Epidemiol
Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia
J Natl Cancer Inst
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women
J Infect Dis
Natural history of human papillomavirus type 16 virus-like particle antibodies in young women
Cancer Epidemiol Biomarkers Prev
Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis
Am J Epidemiol
Age-specific prevalence of infection with human papillomavirus in females: A global review
J Adolesc Health
Risk factors of invasive cervical cancer in Mali
Int J Epidemiol
Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: The International Agency for Research on Cancer HPV Prevalence Surveys
Cancer Epidemiol Biomarkers Prev
Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa
J Med Virol
Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San people of Southern Africa
J Med Virol
Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women
J Clin Microbiol
Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia
J Med Virol
The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children
J Med Virol
Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients
Viral Immunol
Serum antibodies to HPV 16 virus-like particles are not associated with penile cancer in Chinese males
Viral Immunol
Antibodies to human papillomavirus 16; 18, 58, and 6b major capsid proteins among Japanese females
Jpn J Cancer Res
Prevalence of human papillomavirus infection in women in Busan, South Korea
Int J Cancer
Human papillomavirus serology and the risk of esophageal and gastric cancers: Results from a cohort in a high-risk region in China
Int J Cancer
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea
Cancer Epidemiol Biomarkers Prev
Human papillomavirus infection in Ulaanbaatar, Mongolia: A population-based study
Cancer Epidemiol Biomarkers Prev
Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, placebo-controlled trial in 176 Korean subjects
Int J Gynecol Cancer
Seroprevalence and risk factors for human papillomavirus in Taiwan
J Trop Pediatr
Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions
Arch Pharm Res
Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer
Arch Pharm Res
Detection of HPV types and neutralizing antibodies in Gansu province, China
J Med Virol
Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: Nested case-control study
J Gen Virol
Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: Interim analysis of a phase II, double-blind, randomized controlled trial at month 7
Int J Gynecol Cancer
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women
J Obstet Gynaecol Res
Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia
Clin Infect Dis
Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia
J Gen Virol
Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials
Curr Med Res Opin
Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups
J Infect Dis
Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women
J Gen Virol
Cited by (33)
Cellular immune responses against natural human papillomavirus infections among men in Kisumu, Kenya
2020, Clinical ImmunologyMucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany — Results from a nationwide population-based survey
2019, International Journal of Infectious DiseasesCitation Excerpt :In contrast to other studies, we did not observe in older age groups a lower seroprevalence in vaccine-relevant HPV types, except for HPV6 and HPV58 in males. This lower seroprevalence in older age groups was explained by other authors as a result of cohort effects or waning antibodies, even though the humoral response is considered to be relatively stable over time (Newall et al., 2008; Ryser et al., 2017; Tiggelaar et al., 2012; Wang et al., 2003). In general, HPV prevalences in men are described to be less influenced by age compared to women (Giuliano et al., 2011).
High-risk human papillomavirus seroprevalence in men and women of six different ethnicities in Amsterdam, the Netherlands: The HELIUS study
2017, Papillomavirus ResearchCitation Excerpt :However, the slight trends observed indicated an increase in hrHPV seropositivity by age starting at different ages among Dutch (~40 years), Ghanaian (~30 years), and Moroccan (~35 years) women, while among African Surinamese participants hrHPV seropositivity did not change by age. The pattern found among South-Asian Surinamese women was similar to that described in the literature [38–40]. Among women, a sexual debut at a young age was associated with hrHPV seropositivity.
Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels
2016, Journal of Clinical VirologyCitation Excerpt :The antibody responses to the HPV capsid are known to be stable over time, providing a useful measure of cumulative HPV exposure [4]. Most HPV serology studies performed to date have been restricted to HPV-16 and -18 [5]. For Thailand, only HPV-16 and -18 seroprevalences have been described and not in relation to the cervical cancer [6].
Human Papillomavirus Vaccine: Continuation, Completion, and Missed Opportunities
2016, Journal of Pediatric and Adolescent GynecologySerum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types
2013, Journal of Clinical VirologyCitation Excerpt :The most commonly used method for HPV serology has been ELISA using HPV L1 VLPs, a method known to give comparable results to the PsV-Luminex method.14 Most ELISA studies have only used the HPV types included in the quadrivalent vaccine (HPV-6,-11,-16,-18).11 Our HPV-16 and -18 seroprevalences are similar to those reported in a multi-country European study.25
J.S. Smith has received research grants, honoraria, or consultancy fees from GSK or Merck within the last 5 years. No other authors on this manuscript have any conflicts of interest related to this work. A GlaxoSmithKline representative read the article before submission for publication but had no role in study design, analysis of data, or the decision to submit the manuscript for publication. The first draft of the manuscript was jointly written by J. Ji, M.J. Lin, and S.M. Tiggelaar.
- 1
S.M. Tiggelaar and M.J. Lin contributed equally and are co-first authors.